Payment overview · 2025
General Payments
$415.39
21 reported records · 10 companies
Healthcare provider profile · identity verified
Shawn Daniel Couture, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RIVERSIDE, CA · NPI 1548464175
Verified facts
What the public records show
CMS Open Payments records show Shawn Daniel Couture, M.D. received $415.39 in general payments during 2025 across 21 reported records.
Novartis Pharmaceuticals Corporation accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $95.81 | 23.1% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $65.49 | 15.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.83 | 13.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.04 | 11.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.17 | 9.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.24 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.82 | 6.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.03 | 4.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.98 | 4.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.98 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.39 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $95.81 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $65.49 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.83 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.83 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 149 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 408 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 88 |
| Losartan Potassium | Losartan Potassium | 292 | 89 |
| Omeprazole | Omeprazole | 252 | 62 |
| Lisinopril | Lisinopril | 247 | 71 |
| Metformin Hcl | Metformin Hcl | 187 | 56 |
| Tramadol Hcl | Tramadol Hcl | 186 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 57 |
| Gabapentin | Gabapentin | 170 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 165 | 45 |
| Glipizide | Glipizide | 163 | 36 |
| Eliquis | Apixaban | 157 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 47 |
| Alendronate Sodium | Alendronate Sodium | 151 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 31 |
| Simvastatin | Simvastatin | 136 | 35 |
| Furosemide | Furosemide | 124 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 34 |
| Potassium Chloride | Potassium Chloride | 110 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 31 |
| Carvedilol | Carvedilol | 107 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 27 |
| Montelukast Sodium | Montelukast Sodium | 93 | 34 |
| Ezetimibe | Ezetimibe | 92 | 29 |
| Meloxicam | Meloxicam | 87 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 23 |
| Prednisone | Prednisone | 79 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 28 |
| Ibuprofen | Ibuprofen | 73 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 12 |
| Benazepril Hcl | Benazepril Hcl | 69 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 15 |
| Trazodone Hcl | Trazodone Hcl | 67 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 16 |
| Allopurinol | Allopurinol | 62 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 18 |
| Sertraline Hcl | Sertraline Hcl | 56 | 17 |
| Atenolol | Atenolol | 55 | 21 |
| Finasteride | Finasteride | 47 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 12 |
| Chlorthalidone | Chlorthalidone | 44 | 17 |
| Glipizide Er | Glipizide | 44 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Spironolactone | Spironolactone | 43 | 14 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 24 |
| Levofloxacin | Levofloxacin | 35 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 13 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 23 |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | 13 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Azithromycin | Azithromycin | 21 | 19 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Glyburide | Glyburide | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.39 · 21 records | Novartis Pharmaceuticals Corporation | AREXVY, Dexcom G6 Transmitter, ENTRESTO, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error